Patents by Inventor Scott Collibee
Scott Collibee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260098018Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.Type: ApplicationFiled: July 7, 2025Publication date: April 9, 2026Inventors: Bradley P. MORGAN, Chris EVANS, Pu-Ping LU, Makoto YAMASAKI, Wenyue WANG, Scott COLLIBEE, Takuya MAKINO, Kazuyuki TSUCHIYA, Toshio KUROSAKI, Susumu YAMAKI, Eriko HONJO, Yuka KOIZUMI, Naoto KATOH, Ryuichi SEKIOKA, Ikumi KURIWAKI
-
Patent number: 12441691Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.Type: GrantFiled: April 1, 2024Date of Patent: October 14, 2025Assignee: CYTOKINETICS, INC.Inventors: Bradley P. Morgan, Chris Evans, Pu-Ping Lu, Makoto Yamasaki, Wenyue Wang, Scott Collibee, Takuya Makino, Kazuyuki Tsuchiya, Toshio Kurosaki, Susumu Yamaki, Eriko Honjo, Yuka Koizumi, Naoto Katoh, Ryuichi Sekioka, Ikumi Kuriwaki
-
Publication number: 20250296916Abstract: Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, R2, R3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of using a compound of formula (I), or a pharmaceutically acceptable salt thereof, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.Type: ApplicationFiled: May 3, 2023Publication date: September 25, 2025Inventors: Chris EVANS, Bradley P. MORGAN, Scott COLLIBEE, Takuya MAKINO, Toshio KUROSAKI, Eriko HONJO, Yuka KOIZUMI
-
Publication number: 20240368091Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.Type: ApplicationFiled: April 1, 2024Publication date: November 7, 2024Inventors: Bradley P. MORGAN, Chris EVANS, Pu-Ping LU, Makoto YAMASAKI, Wenyue WANG, Scott COLLIBEE, Takuya MAKINO, Kazuyuki TSUCHIYA, Toshio KUROSAKI, Susumu YAMAKI, Eriko HONJO, Yuka KOIZUMI, Naoto KATOH, Ryuichi SEKIOKA, Ikumi KURIWAKI
-
Patent number: 11981644Abstract: Provided herein are compounds of formula (1): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.Type: GrantFiled: November 5, 2021Date of Patent: May 14, 2024Assignee: CYTOKINETICS, INC.Inventors: Bradley P. Morgan, Chris Evans, Pu-Ping Lu, Makoto Yamasaki, Wenyue Wang, Scott Collibee, Takuya Makino, Kazuyuki Tsuchiya, Toshio Kurosaki, Susumu Yamaki, Eriko Honjo, Yuka Koizumi, Naoto Katoh, Ryuichi Sekioka, Ikumi Kuriwaki
-
Publication number: 20230083960Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.Type: ApplicationFiled: November 5, 2021Publication date: March 16, 2023Inventors: Bradley P. MORGAN, Chris Evans, Pu-Ping Lu, Makoto Yamasaki, Wenyue Wang, Scott Collibee, Takuya Makino, Kazuyuki Tsuchiya, Toshio Kurosaki, Susumu Yamaki, Eriko Honjo, Yuka Koizumi, Naoto Katoh, Ryuichi Sekioka, Ikumi Kuriwaki, Denise Andersen
-
Publication number: 20230026651Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 20, 2022Publication date: January 26, 2023Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
-
Publication number: 20220332708Abstract: The present disclosure relates to sulfonamide compounds and pharmaceutically acceptable salts thereof as cardiac sarcomere activators.Type: ApplicationFiled: April 5, 2022Publication date: October 20, 2022Inventors: Jeffrey GARDINA, Aroop CHANDRA, Luke W. ASHCRAFT, Scott COLLIBEE, Chihyuan CHUANG, Alex MUCI - DECEASED, Bradley P. MORGAN, Antonio ROMERO, Michael JOHNSON, David MOEBIUS, Hanmo ZHANG, Felix GONZALEZ
-
Patent number: 11369565Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 28, 2020Date of Patent: June 28, 2022Assignee: CYTOKINETICS, INC.Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
-
Publication number: 20210045997Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 28, 2020Publication date: February 18, 2021Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
-
Patent number: 10765624Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 13, 2019Date of Patent: September 8, 2020Assignee: CYTOKINETICS, INC.Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
-
Publication number: 20190307677Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 13, 2019Publication date: October 10, 2019Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
-
Patent number: 10272030Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 10, 2017Date of Patent: April 30, 2019Assignee: Cytokinetics, Inc.Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
-
Patent number: 10076519Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 20, 2017Date of Patent: September 18, 2018Assignee: CYTOKINETICS, INC.Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R. Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang, Pu-Ping Lu, Antonio Romero
-
Patent number: 9994528Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 11, 2015Date of Patent: June 12, 2018Assignee: Cytokinetics, Inc.Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R Muci, Xiangping Qian, Antonio Romero, Jeffrey Warrington, Zhe Yang
-
Publication number: 20180064637Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 10, 2017Publication date: March 8, 2018Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
-
Publication number: 20170281621Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 20, 2017Publication date: October 5, 2017Inventors: Luke W. ASHCRAFT, Gustave BERGNES, Scott COLLIBEE, Chihyuan CHUANG, Jeff GARDINA, Bradley P. MORGAN, Alex R. MUCI, Xiangping QIAN, Jeffrey WARRINGTON, Zhe YANG, Pu-Ping LU, Antonio ROMERO
-
Patent number: 9730886Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 12, 2015Date of Patent: August 15, 2017Assignee: Cytokinetics, Inc.Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
-
Patent number: 9604965Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 12, 2015Date of Patent: March 28, 2017Assignee: Cytokinetics, Inc.Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R. Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang, Pu-Ping Lu, Antonio Romero
-
Publication number: 20160289211Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising sing a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 4, 2016Publication date: October 6, 2016Inventors: Luke W. ASHCRAFT, Gustave BERGNES, Chihyuan CHUANG, Scott COLLIBEE, Pu-Ping LU, Bradley MORGAN, Alex MUCI, Xiangping QIAN, Jeffrey WARRINGTON, Zhe YANG